Pacira Pharmaceuticals, Inc
PharmaParsippany, New Jersey, United States · Est. 2004 · 900 employees
Pacira Pharmaceuticals is a pharmaceutical company focused on developing and commercializing non-opioid pain management and anesthetic products for healthcare providers and patients.
3
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
2
Indications↗
Distinct diseases across all programs
82
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
Pipeline Snapshot
By Phase
3 drugs in development
Phase 22
Phase 11
By Therapeutic Area
top 1
Musculoskeletal
375%
R&D Momentum
30/100
Pipeline Velocity
6/100
Trial Completion Rate
75/100
Pipeline Concentration
63/100
Pipeline Freshness
27/100
Activity
Recent Activity
Earlier
Jul 25, 2025TrialA Study to Evaluate an Intra-Articular Injection of ZILRETTA Versus Triamcinolone Acetonide, Immediate Release in Subjects With Osteoarthritis of the Hip
Feb 26, 2025TrialA Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the Knee
Mar 29, 2024TrialStudy to Evaluate the Pharmacokinetics and Safety of EXPAREL for Postoperative Analgesia in Subjects Undergoing Cardiac Surgery
Feb 5, 2024TrialZILRETTA in Subjects With Shoulder Osteoarthritis
Apr 18, 2023TrialPhase 1, Dose Escalation Study to Evaluate of Safety, Pharmacokinetics and Pharmacodynamics of Liposomal Bupivacaine 13.3 Administered Via a Single Intrathecal Injection to Healthy Volunteers
Feb 15, 2022TrialPhase 3, Sciatic Nerve Block With EXPAREL for Subjects Undergoing Bunionectomy
Jan 18, 2022TrialPhase 3 Adductor Canal Block With EXPAREL in Subjects Undergoing Primary Unilateral Total Knee Arthroplasty
4 more events
Mar 15, 2021TrialStudy to Evaluate the Safety and Tolerability of FX301 in Patients Undergoing Bunionectomy
Oct 20, 2020TrialStudy to Evaluate the Efficacy, Safety, and Pharmacokinetics of EXPAREL, EXPAREL Admixed With Bupivacaine HCl vs. Bupivacaine HCl Administered as Combined Sciatic and Saphenous Nerve Blocks for Postsurgical Analgesia in Subjects Undergoing Lower Extremity Surgeries
Jun 15, 2020TrialPhase 3, Randomized, Double Blinded, Active Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of EXPAREL Admixed With Bupi vs. Bupi Only Administered as Combined Sciatic and Adductor Canal Nerve Block for Postsurgical Analgesia in Lower Extremity Surgeries
Jun 8, 2020TrialEvaluation of Safety, Pharmacokinetics and Pharmacodynamics of EXPAREL® Administered Via a Single Intrathecal Injection to Healthy Volunteers
Details
Company Info
Company Overview
$2.5B
Mkt Cap
$600.0M
Revenue
—
Cash
CEODeepak Chopra
Founded2004
Employees900
HQParsippany, New Jersey, United States
Websitepacira.com
LinkedInCompany Page
Therapeutic Focus
Pain managementRegional anesthesiaOrthopedicsPost-operative pain
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Musculoskeletal
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)